Literature DB >> 8380659

Rescue of infectivity by in vitro transcapsidation of rotavirus single-shelled particles.

D Chen1, R F Ramig.   

Abstract

We investigated the possibility of rescuing the infectivity of noninfectious single-shelled rotavirus particles by in vitro transcapsidation. The soluble outer capsid proteins VP4 and VP7 were prepared by EDTA treatment of double-shelled (ds) particles of SA11-4F (G serotype 3), followed by removal of single-shelled (ss) particles by three sequential rounds of centrifugation. Ss-particles of B223 (G serotype 10) were prepared by two cycles of EDTA treatment of ds-particles followed by iospycnic CsCl gradient purification. A trace of infectivity (< 1000 PFU/ml) was always detected in the preparations of ss-particles, while no detectable infectivity (< 5 PFU/ml) was present in the preparations of outer capsid proteins. By mixing soluble outer capsid proteins VP4 and VP7 purified from SA11-4F and ss-particles of B223 at acidic pH (5.4), ds-like, transcapsidated particles were obtained. The transcapsidated particles were indistinguishable from genuine ds-particles by negative stain electron microscopy. However, the particles had a density intermediate between that of ds- and ss-particles. Protease-resistance studies revealed that VP7 was assembled onto transcapsidated particles in a resistant (native) form, but VP4 associated with the particles was completely protease sensitive. Viral infectivity was rescued by in vitro transcapsidation as indicated by a 500- to 1000-fold increase over background. The increased infectivity was neutralized by antiserum against SA11 (outer capsid donor), but not by antiserum against B223 (ss-particle donor). The transcapsidated particles formed small plaques like the B223 parent, and all the infectious progeny viruses contained the B223 genome. These results strongly indicate that the observed increase of infectivity was the result of in vitro transcapsidation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8380659     DOI: 10.1006/viro.1993.1057

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  Assembly of highly infectious rotavirus particles recoated with recombinant outer capsid proteins.

Authors:  Shane D Trask; Philip R Dormitzer
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

2.  cis-Acting signals that promote genome replication in rotavirus mRNA.

Authors:  J T Patton; M Wentz; J Xiaobo; R F Ramig
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

3.  The 3'-terminal consensus sequence of rotavirus mRNA is the minimal promoter of negative-strand RNA synthesis.

Authors:  M J Wentz; J T Patton; R F Ramig
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Characterization and replicase activity of double-layered and single-layered rotavirus-like particles expressed from baculovirus recombinants.

Authors:  C Q Zeng; M J Wentz; J Cohen; M K Estes; R F Ramig
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

5.  Rotavirus-induced fusion from without in tissue culture cells.

Authors:  M M Falconer; J M Gilbert; A M Roper; H B Greenberg; J S Gavora
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

6.  Template-dependent, in vitro replication of rotavirus RNA.

Authors:  D Chen; C Q Zeng; M J Wentz; M Gorziglia; M K Estes; R F Ramig
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

7.  In vitro recoating of reovirus cores with baculovirus-expressed outer-capsid proteins mu1 and sigma3.

Authors:  K Chandran; S B Walker; Y Chen; C M Contreras; L A Schiff; T S Baker; M L Nibert
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

8.  Further characterisation of rotavirus cores: Ss(+)RNAs can be packaged in vitro but packaging lacks sequence specificity.

Authors:  Ulrich Desselberger; James Richards; Luba Tchertanov; Jean Lepault; Andrew Lever; Oscar Burrone; Jean Cohen
Journal:  Virus Res       Date:  2013-10-01       Impact factor: 3.303

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.